The Fourth Department of Thyroid and Breast Surgery, Cangzhou Central Hospital, Cangzhou, China.
Pak J Pharm Sci. 2023 May;36(3(Special)):935-939.
The aim of this study was to analyze the clinical efficacy of Apatinib plus Ba Zhen granules in advanced unresectable differentiated thyroid cancer and its influence on immune factors. Sixty patients with advanced unresectable differentiated thyroid cancer in our hospital between January 2018 and December 2019 were selected and randomized to the control group and the observation group (30 cases in each group). After treatment, the observation group yielded higher serum levels of Cyfra21.1 and Gal-3, but lower SIL-2R levels than the control group. After treatment, the two groups obtained a marked increase in CD3+ and CD4+ levels and a decrease in CD8+ level, in which the observation group has higher levels of CD3+ and CD4+ and lower levels of CD8+ than the control group. After treatment, the serum FT3 and FT4 levels sharply increased and serum TSH levels declined significantly, with higher levels of FT3 and FT4 and lower levels of TSH observed in the observation group. The incidence of adverse reactions didn't significantly differ between groups. In advanced unresectable differentiated thyroid cancer, apatinib remarkably inhibits disease development. The combination of Apatinib and Ba Zhen granules adjusts immune factors and improves thyroid function, with a low incidence of adverse reactions and promising efficacy.
本研究旨在分析阿帕替尼联合巴珍颗粒治疗晚期不可切除分化型甲状腺癌的临床疗效及其对免疫因子的影响。选取我院 2018 年 1 月至 2019 年 12 月收治的 60 例晚期不可切除分化型甲状腺癌患者，随机分为对照组和观察组，每组 30 例。治疗后，观察组血清细胞角蛋白 19 片段 21.1（Cyfra21.1）和人附睾蛋白 4（Gal-3）水平高于对照组，可溶性白细胞介素 2 受体（SIL-2R）水平低于对照组。治疗后，两组 CD3+和 CD4+水平明显升高，CD8+水平明显下降，其中观察组 CD3+和 CD4+水平高于对照组，CD8+水平低于对照组。治疗后，两组游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）水平明显升高，促甲状腺激素（TSH）水平明显下降，且观察组 FT3、FT4 水平更高，TSH 水平更低。两组不良反应发生率无显著差异。阿帕替尼能显著抑制晚期不可切除分化型甲状腺癌的发展，阿帕替尼联合巴珍颗粒能调节免疫因子，改善甲状腺功能，不良反应发生率低，疗效确切。
